Document is current
Any future updates will be listed below
-
Authors
López-Polo, Vanessa https://orcid.org/0000-0001-6165-2510
Maus, Mate https://orcid.org/0000-0002-2128-2479
Zacharioudakis, Emmanouil
Lafarga, Miguel
Attolini, Camille Stephan-Otto https://orcid.org/0000-0001-8045-320X
Marques, Francisco D. M.
Kovatcheva, Marta https://orcid.org/0000-0002-2536-1043
Gavathiotis, Evripidis https://orcid.org/0000-0001-6319-8331
Serrano, Manuel https://orcid.org/0000-0001-7177-9312
- License Information
-
More Information
Article History
Received: 20 October 2023
Accepted: 6 August 2024
First Online: 27 August 2024
Competing interests
: M.S. is shareholder of Senolytic Therapeutics, Inc., Life Biosciences, Inc., Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc. M.S. has been consultant, until the end of 2022, of Rejuveron Senescence Therapeutics, AG, and Altos Labs, Inc. M.K. has ongoing or completed research contracts with Galapagos NV, Rejuveron Senescence Therapeutics, and mesoestetic®. E.Z. and E.G. are inventors in patents submitted by Albert Einstein College of Medicine that protect compounds, compositions, and methods for controlling mitofusins for the treatment of diseases and disorders. E.G. has received compensation for consulting and has equity ownership from BaxGen Therapeutics, Comorin Therapeutics, BeanPod Biosciences, Life Biosciences, and Stelexis Biosciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare no competing interests.
